LC-MS/MS based detection and characterization of covalent glutathione modifications formed by reactive drug of abuse metabolites

References

• Attia SM. (2010). Deleterious effects of reactive metabolites. Oxid Med Cell Longev 3:238–53.
   PubMed Web of Science ®Google Scholar
• Blair IA. (2010). Analysis of endogenous glutathione-adducts and their metabolites. Biomed Chromatogr 24:29–38.
   PubMed Web of Science ®Google Scholar
• Capela JP, Macedo C, Branco PS, et al. (2007). Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146:1743–57.
   PubMed Web of Science ®Google Scholar
• Dahlin DC, Miwa GT, Lu AY, Nelson SD. (1984). N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 81:1327–31.
   PubMed Web of Science ®Google Scholar
• de Almeida CAA, Oliveira MS, Mallmann CA, Martins AF. (2015). Determination of the psychoactive drugs carbamazepine and diazepam in hospital effluent and identification of their metabolites. Environ Sci Pollution Res 22:17192–201.
   PubMed Web of Science ®Google Scholar
• DeCaprio AP. (1997). Biomarkers: coming of age for environmental health and risk assessment. Environ Sci Technol 31:1837–48.
   Web of Science ®Google Scholar
• Dieckhaus CM, Fernandez-Metzler CL, King R, et al. (2005). Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem Res Toxicol 18:630–8.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016). Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity. Drug Metab Rev 48:80–7.
   PubMed Web of Science ®Google Scholar
• Dragovic S, Gunness P, Ingelman-Sundberg M, et al. (2013). Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos 41:651–8.
   PubMed Web of Science ®Google Scholar
• Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16.
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Tolosa L, Donato MT. (2016). Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol 36:752–68.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2003). Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch Biochem Biophys 409:59–71.
   PubMed Web of Science ®Google Scholar
• Ikehata K, Duzhak TG, Galeva NA, et al. (2008). Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo. Chem Res Toxicol 21:1432–42.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shibata Y, Takahashi H, et al. (2009). A trapping method for semi-quantitative assessment of reactive metabolite formation using [35S]cysteine and [14C]cyanide. Drug Metab Pharmacokinet 24:245–54.
   PubMed Web of Science ®Google Scholar
• Jerina DM, Daly JW. (1974). Arene oxides: a new aspect of drug metabolism. Science 185:573–82.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS. (2011). Handling reactive metabolite positives in drug discovery: what has retrospective structure-toxicity analyses taught us?. Chem Biol Interact 192:46–55.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Gardner I, Obach RS, et al. (2005). A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:161–225.
   PubMed Web of Science ®Google Scholar
• Kovacic P, Cooksy AL. (2005). Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species. Med Hypoth 64:357–66.
   PubMed Web of Science ®Google Scholar
• Li Y, Wu L, Gu Y, et al. (2014). Metabolism of aildenafil in vivo in rats and in vitro in mouse, rat, dog, and human liver microsomes. Drug Test Anal 6:552–62.
   PubMed Web of Science ®Google Scholar
• Lu D, Sullivan MM, Phillips MB, Peterson LA. (2009). Degraded protein adducts of cis-2-butene-1,4-dial are urinary and hepatocyte metabolites of furan. Chem Res Toxicol 22:997–1007.
   PubMed Web of Science ®Google Scholar
• Meneses-Lorente G, Sakatis MZ, Schulz-Utermoehl T, et al. (2006). A quantitative high-throughput trapping assay as a measurement of potential for bioactivation. Anal Biochem 351:266–72.
   PubMed Web of Science ®Google Scholar
• Meyer MR, Maurer HH. (2010). Metabolism of designer drugs of abuse: an updated review. Curr Drug Metab 11:468–82.
   PubMed Web of Science ®Google Scholar
• Meyer MR, Richter LHJ, Maurer HH. (2014). Methylenedioxy designer drugs: mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency. Anal Chim Acta 822:37–50.
   PubMed Web of Science ®Google Scholar
• Miller JA, Miller EC. (1965). Metabolism of drugs in relation of carcinogenicity. Ann N Y Acad Sci 123:125–40.
   PubMed Web of Science ®Google Scholar
• Ndikum-Moffor FM, Munson JW, Bokinkere NK, et al. (1998). Immunochemical detection of hepatic cocaine-protein adducts in mice. Chem Res Toxicol 11:185–92.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Nelson SD. (2011). Rearrangement reactions catalyzed by cytochrome P450s. Arch Biochem Biophys 507:95–110.
   PubMed Web of Science ®Google Scholar
• Schaber G, Stevens I, Gaertner HJ, et al. (1998). Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol 46:453–9.
   PubMed Web of Science ®Google Scholar
• Schadt S, Simon S, Kustermann S, et al. (2015). Minimizing DILI risk in drug discovery - A screening tool for drug candidates. Toxicol in Vitro 30:429–37.
   PubMed Web of Science ®Google Scholar
• Schneider KJ, DeCaprio AP. (2013). Covalent thiol adducts arising from reactive intermediates of cocaine biotransformation. Chem Res Toxicol 26:1755–64.
   PubMed Web of Science ®Google Scholar
• Shimizu E, Hashimoto K, Komatsu N, Iyo M. (2002). Roles of endogenous glutathione levels on 6-hydroxydopamine-induced apoptotic neuronal cell death in human neuroblastoma SK-N-SH cells. Neuropharmacol 43:434–43.
   PubMed Web of Science ®Google Scholar
• Thompson RA, Isin EM, Li Y, et al. (2011). Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 192:65–71.
   PubMed Web of Science ®Google Scholar
• Todaka T, Ishida T, Kita H, et al. (2005). Bioactivation of morphine in human liver: isolation and identification of morphinone, a toxic metabolite. Biol Pharm Bull 28:1275–80.
   PubMed Web of Science ®Google Scholar
• Wennig R. (2000). Potential problems with the interpretation of hair analysis results. Forensic Sci Int 107:5–12.
   PubMed Web of Science ®Google Scholar
• Xie C, Zhong D, Chen X. (2013). A fragmentation-based method for the differentiation of glutathione conjugates by high-resolution mass spectrometry with electrospray ionization. Anal Chim Acta 788:89–98.
   PubMed Web of Science ®Google Scholar
• Yamada H, Ishii Y, Oguri K. (2005). Metabolism of drugs of abuse: its contribution to the toxicity and the inter-individual differences in drug sensitivity. J Health Sci 51:1–7.
   Google Scholar
• Yamaoka T, Kitamura Y. (2015). Characterization of a highly sensitive and selective novel trapping reagent, stable isotope labeled glutathione ethyl ester, for the detection of reactive metabolites. J Pharmacol Toxicol Meth 76:83–95.
   PubMed Web of Science ®Google Scholar
• Zhu M, Ma L, Zhang H, Humphreys WG. (2007). Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering. Anal Chem 79:8333–41.
   PubMed Web of Science ®Google Scholar